A New Dawn: FDA Greenlights CRISPR Gene-Editing for Sickle Cell Disease Treatment
In a groundbreaking move, the United States Food and Drug Administration (FDA) has given the green light to a revolutionary gene-editing treatment for sickle cell disease. This marks a significant milestone in the field of medical science, as it represents the first approval of cell-based gene therapies for this debilitating blood disorder. The FDA has […]
Continue Reading